This site uses cookies. By continuing to use this site you agree to our use of cookies. To find out more, see our Privacy and Cookies policy.
Paper The following article is Open access

The radiosensitizing effect of platinum nanoparticles in proton irradiations is not caused by an enhanced proton energy deposition at the macroscopic scale

, , , , , , , , , and

Published 29 July 2022 © 2022 The Author(s). Published on behalf of Institute of Physics and Engineering in Medicine by IOP Publishing Ltd
, , Citation C Behrends et al 2022 Phys. Med. Biol. 67 155023 DOI 10.1088/1361-6560/ac80e6

0031-9155/67/15/155023

Abstract

Objective. Due to the radiosensitizing effect of biocompatible noble metal nanoparticles (NPs), their administration is considered to potentially increase tumor control in radiotherapy. The underlying physical, chemical and biological mechanisms of the NPs' radiosensitivity especially when interacting with proton radiation is not conclusive. In the following work, the energy deposition of protons in matter containing platinum nanoparticles (PtNPs) is experimentally investigated. Approach. Surfactant-free monomodal PtNPs with a mean diameter of (40 ± 10) nm and a concentration of 300 μg ml−1, demonstrably leading to a substantial production of reactive oxygen species (ROS), were homogeneously dispersed into cubic gelatin samples serving as tissue-like phantoms. Gelatin samples without PtNPs were used as control. The samples' dimensions and contrast of the PtNPs were verified in a clinical computed tomography scanner. Fields from a clinical proton machine were used for depth dose and stopping power measurements downstream of both samples types. These experiments were performed with a variety of detectors at a pencil beam scanning beam line as well as a passive beam line with proton energies from about 56–200 MeV. Main results. The samples' water equivalent ratios in terms of proton stopping as well as the mean proton energy deposition downstream of the samples with ROS-producing PtNPs compared to the samples without PtNPs showed no differences within the experimental uncertainties of about 2%. Significance. This study serves as experimental proof that the radiosensitizing effect of biocompatible PtNPs is not due to a macroscopically increased proton energy deposition, but is more likely caused by a catalytic effect of the PtNPs. Thus, these experiments provide a contribution to the highly discussed radiobiological question of the proton therapy efficiency with noble metal NPs and facilitate initial evidence that the dose calculation in treatment planning is straightforward and not affected by the presence of sensitizing PtNPs.

Export citation and abstract BibTeX RIS

Original content from this work may be used under the terms of the Creative Commons Attribution 4.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.

1. Introduction

Based on the idea of enriching tumors with high-Z materials, biocompatible noble metal nanoparticles (NPs) are of great interest in radiobiological research (Schuemann et al 2020). The seminal study of the NPs' radiosensitizing effect was achieved by Hainfeld et al (2008), who demonstrated a dose enhancement effect with x-rays in malignant tumors by gold nanoparticles (AuNPs) using a mouse model. Further experiments and simulations indicated the dose enhancement effect of AuNPs in combination with ionizing radiation, outlining the promising application of NPs in radiotherapy (Mesbahi 2010, Butterworth et al 2012).

In addition to photons, metal NPs or metallic complexes can be combined with particle radiation to potentially induce an enhancement of the radiotherapeutic effect (Usami et al 2005, 2008, Kim et al 2010, Lacombe et al 2017). Using in vitro studies, Polf et al (2011) demonstrated the increased biological effectiveness of protons with AuNPs: A 15%–20% increased efficiency in killing prostate tumor cells was shown in the presence of AuNPs. Furthermore, Li et al (2016) described a dependence of radiosensitizing effects of AuNPs on linear energy transfer (LET) of proton fields.

The mechanism behind the potentially enhanced proton therapy efficiency due to the radiosensitizing effect of metal NPs has not been fully understood yet (Schuemann et al 2020). On the one hand, due to the large atomic number Z of noble metal NPs, particle-induced x-ray emission (PIXE) was assumed as an explanation for the dose enhancement in the surrounding tumor tissue (Kim et al 2010, Polf et al 2011). However, Dollinger (2011) argued based on stopping power calculations that the energy imparted by protons to the NPs is expected to be too low to cause a PIXE-based enhancement effect.

On the other hand, the secondary electrons induced by the protons on their primary track may contribute. Sech et al (2012) postulated an energy conversion of the secondary electron energy into Auger de-excitation in the heavy atoms: they suggested that Auger electrons emitted by secondary electron induced inner-atomic Auger cascades in the NPs cause the radiolysis of the surrounding water molecules leading to free hydroxyl radicals. By assuming that the conversion of energy may cause the enhancement effect, they precluded an increased proton energy deposition. A local microscopic dose effect enhancement around the NPs due to Auger electrons was investigated and confirmed in Monte Carlo studies (Wälzlein et al 2014, Cho et al 2016, Lacombe et al 2017).

In contrast to previous approaches, Sicard-Roselli et al (2014) explained the radiosensitizing effect of AuNPs—though with photon radiation—via a catalytic process occurring at the interface between the NPs and water molecules. The corresponding chemical reactions increase the effectiveness of the radiolysis of water molecules in the immediate vicinity of the NPs.

While there is a discrepancy concerning the interpretation of the process which causes increased radiolysis of water, the important contribution of the resulting reactive oxygen species (ROS) to the enhanced radiotherapy effect has been demonstrated in several works (Kim et al 2012, Li et al 2016, Schlathölter and Eustache 2016, Smith et al 2017). Furthermore, Zwiehoff et al (2021) demonstrated that the enhancement in proton therapy with platinum NPs (PtNPs) is a surface- and not a mass-dependent effect, further indicating that a surface-driven catalytic process is involved.

In order to provide a contribution to the discussed mechanisms, this study intends to verify experimentally that radiosensitizing effects by PtNPs are not correlated with an increased proton energy deposition at the macroscopic scale. For that, surfactant-free PtNPs were produced and tissue-like samples with (PtNP samples) and without injected PtNPs (nonPtNP samples) were manufactured. For confirmation of the fact that the NPs in the samples can potentially increase proton therapy efficiency, the radiosensitizing effect of equivalent colloidal PtNPs in terms of increased ROS generation under proton irradiation was verified. Furthermore, a clinical computed tomography (CT) scan was used to investigate the properties of the PtNP and nonPtNP samples. To investigate the aspects in the energy domain for the radiosensitizing effect of these PtNPs, proton beam measurements with quality assurance devices and three types of experimental setups were performed for the PtNP and nonPtNP samples and compared in terms of the proton dose and energy distribution downstream of the samples. To further assess the impact of PtNPs on treatment planning, spot sizes were analyzed to compare proton scattering effects with and without PtNPs.

Overall, this study examines in detail the energy balance downstream of the PtNP and nonPtNP samples in the beam path and provides the experimental evidence that the underlying radiosensitizing effect cannot be explained by an increased proton energy deposition at the macroscopic scale.

2. Methods

2.1. Manufacturing process of the samples

2.1.1. Pulsed laser ablation in liquids

Surfactant-free PtNPs were produced through pulsed laser ablation (picosecond Nd:YAG laser, Ekspla (Vilnius, Lithuania), Atlantic Series, 10 ps, 1064 nm, 9.6 mJ, 100 kHz) of a platinum target placed in a batch chamber filled with ultra pure water (electrical resistivity: 18.2 MΩ cm at 25 °C) (Waag et al 2021). Figure 1(a) presents a sketch of this method. Focusing of the laser beam was done by an f-theta lens. Utilizing a galvanometric scanner, the focused beam was spirally scanned over the target. A bimodal particle size distribution was obtained through 15 min ablation with a nominal laser fluence of 6.1 J cm−2 on the surface of the target.

Figure 1.

Figure 1. Workflow of the gelatin sample creation. In (a), the pulsed laser ablation in liquids is outlined. (b) Presents the obtained monomodal nanoparticles' size distribution after centrifugation. The derived mass-weighted particle size distribution of 1000 analyzed particles is shown resulting in a mean particle diameter of dmean = (40 ± 10) nm, given with its standard uncertainty. The inset shows a transmission electron micrograph of some platinum nanoparticles (PtNPs). (c) Schematically illustrates the gelation process, from which the gelatin samples are produced upon completion.

Standard image High-resolution image

2.1.2. Centrifugation

To get a monomodal size distribution, the ablated colloid was centrifuged (Hettich, 295 g, 35 min) and the generated pellet was used to isolate the PtNPs. For this, the pellet was diluted with ultra pure water, yielding a mass concentration of 600 μg ml−1. A transmission electron micrograph of the PtNPs and the obtained particle diameter distribution with a mean value of dmean = (40 ± 10) nm is shown in figure 1(b).

2.1.3. Gelation process

The gelation process of the samples with and without PtNPs is pictured in figure 1(c). 25 g gelatin were left to swell in 250 ml cold ultra pure water for 10 minutes. While stirring, the solution was heated to 40 °C until the gelatin dissolved. Then, 250 ml of water or colloidal PtNPs, each previously tempered to 30 °C, were added under stirring to the gelatin solution. The mixture with PtNPs resulted in a final concentration of 300 μg ml−1 (a percentage weighting of platinum to gelatin mass of 0.03 wt%). Both mixtures were poured into templates, resulting in a filling height of 20 mm. After curing, the resulting gels were cut into cuboids which yield the PtNP and nonPtNP samples. They have lateral dimensions of about 30 × 30 mm2 and a vertical dimension of roughly 20 mm given by the filling height (see figure 1(c)). The latter indicates the distance in the material traversed by the beam. Since this sample thickness is difficult to determine accurately due to the soft properties of gelatin, the ratio of this sample thickness H and the sample's water equivalent thickness (WET) (Zhang and Newhauser 2009) are used in the following.

2.2. Verification of ROS generation of PtNPs during proton irradiation

In order to additionally verify the enhancement effect of the samples' PtNPs in preparation for the following experiments, the ROS generation during proton irradiation was quantified with water phantoms. An absorbed dose of 5 Gy and the setup described in Zwiehoff et al (2021) was used. Briefly, terephthalic acid (TA) was added to the colloidal PtNPs before irradiation. During proton irradiation, the generated hydroxyl radicals react with the TA forming 2-hydroxyterephthalic acid (2-OH-TA), whose fluorescent signal could be measured to determine the concentration of hydroxyl radicals. To obtain the fluorescent intensity, the PtNPs were precipitated directly after the irradiation, avoiding any cross or quenching effects. Colloidal PtNPs where created in concentrations of 50, 100, 200 and 300 μg ml−1 having a total available surface area from 3 to 17 cm2 ml−1. Figure 2 presents the effect of the increasing PtNPs' concentration on the generated 2-OH-TA. A higher concentration of PtNPs leads to an increased production of 2-OH-TA in comparison to the reference, up to an increase by a factor greater than 2 at the concentration of 300 μg ml−1. At all concentrations, the samples with colloidal PtNPs were able to generate more radicals than the reference without PtNPs, indicating a sensitizing effect of the implemented PtNPs.

Figure 2.

Figure 2. Generated 2-OH-TA concentration during proton irradiation of platinum nanoparticles (PtNPs) in presence of terephthalic acid (TA). PtNPs' concentration was increased while irradiation fields were kept constant (absorbed dose of 5 Gy). The standard uncertainties shown with the error bars arrive from the measurement of nine independent samples. The horizontal line at 155 nmol l−1 represents the concentration of 2-OH-TA in the absence of PtNPs during proton irradiation serving as the reference level.

Standard image High-resolution image

2.3. Treatment planning study

In order to verify the homogeneity and geometric properties of the samples, x-ray acquisitions of two PtNP and two nonPtNP samples were performed with a Brilliance Big Bore scanner (Philips, Hamburg, Germany). The samples of each type were placed diagonally to the CT axis to mitigate artifacts, e.g. reconstruction artifacts induced by the sharp corners. A high resolution scan protocol with a reconstructed lateral pixel size of 0.65 mm and a tube voltage of 80 kV was used. Subsequently, the outer contour of the phantoms was generated gray level based in the clinical treatment planning system RayStation 6.99 (RaySearch Laboratories, Stockholm, Sweden). The CT numbers CTnum in Hounsfield Units (HU) were evaluated in regions of interest (ROIs) contracted by 5 mm with respect to the outer samples' contours. The CT contrast of the NPs is defined as the difference of the mean CTnum of the samples: ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ = $\overline{{{CT}}_{\mathrm{num}}}(\mathrm{PtNP})$$\overline{{{CT}}_{\mathrm{num}}}(\mathrm{nonPtNP})$.

The so-obtained mean CT contrast ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ was used to determine the physical thicknesses of the samples as accurately as possible. For that, the samples' outer contours were again delineated based on their gray levels under consideration of ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$. The outer contours were defined at the 50% level of the average CT numbers in the contracted ROIs. Thus, 50% of ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ was used for the specification of the samples volumes. To identify the samples' physical thicknesses, well-defined matchstick shaped volumes as presented in red in figure 3 with a small cross section overlapping with the sample volumes in beam direction were used as help structures. By determining the intersection (yellow contours in figure 3), the long edge length of the intersection volume (which corresponds to the sample thickness) could be determined via the known volume and edge lengths of the small cross sectional area. The mean thickness of each sample type was established over five repetitions while varying the lateral position of the help structures (see figure 3). However, since this thickness depends on the HU-scale, its gray scale independent thickness ratio H was calculated with

Equation (1)

where hPtNP and hnonPtNP are the calculated mean sample thicknesses at a sample-specific gray level window. With the help of H, the necessity of exactly estimating the physical sample thickness and the attendant uncertainties, as well as possible height compressions when stacking the samples, were circumvented.

Figure 3.

Figure 3. Method for identifying the sample thicknesses using help structures: matchstick-shaped volumes (red) with known edge lengths are used to determine the sample's thickness via their intersection volume (yellow) with the sample's outer contour (blue). The coronal view with the contours is shown on the left and the 3D view on the right.

Standard image High-resolution image

Based on the determined CT contrast from the imaging study, the influence of PtNPs applied in the tumor on treatment planning in terms of dose calculation was investigated. For this purpose, three exemplary pediatric patients with brain tumors (two ependymoma and one medulloblastoma) with slightly different localizations were selected. On a copy of the original planning CT and using the clinical calibration curves, the density of the planning target volume (PTV) was overwritten according to the density with the additional determined CT contrast ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ above. Subsequently, the original highly conformal dose distribution in the PTV was recalculated on the CT with the overwritten PTV density. The difference in the PTV's dose coverage ΔD98% (the dose of the PTV, which is at least delivered to 98% of the PTV's volume) was calculated with ΔD98% = D98%(original)/D98%(overwritten) − 1, where D98%(original) is the PTV's dose D98% with original density and D98%(overwritten) the PTV's dose D98% with overwritten density.

2.4. Measurements of depth dose and energy deposition

The experiments were performed at the West German Proton Therapy Centre Essen (WPE), a clinical proton therapy center, equipped with an IBA ProteusPlus proton therapy system (IBA PT, Louvain-La-Neuve, Belgium) based on a 230 MeV isochronous cyclotron. Both, the pencil beam scanning (PBS) technique as well as a passive treatment technique of an IBA ProteusPlus proton therapy system (IBA PT, Louvain-La-Neuve, Belgium) were used as elucidated in the following.

In order to measure the energy balance outside the samples in multifaceted ways, three independent measurement setups and detectors pictured in figure 4 were used. These measurements allow to infer the energy deposition of the protons in the samples.

Figure 4.

Figure 4. Experimental setup of the three measurement methods: in (a) the measurement of the depth dose curves with the vertically aligned Giraffe detector is presented. (b) Shows the setup at the eyeline with the motorized water phantom and the Advanced Markus chamber, where the depth dose was also monitored. The measurement of the deposited charge with the semiconductor pixel detector is illustrated in (c). In setup (a) and (b) the samples with platinum nanoparticles (PtNP samples) and without (nonPtNP samples) were measured sequentially and in setup (c) simultaneously.

Standard image High-resolution image

2.4.1. Multi-layer ionization chamber Giraffe

A clinical PBS beam line equipped with an IBA PBS dedicated nozzle was used to measure the depth dose distribution downstream of the samples. A multi-layer ionization chamber (MLIC) Giraffe detector (IBA Dosimetry, Schwarzenbruck, Germany) with an electrode diameter of 12 cm was captured with mono-energetic single co-axial pencil beam spots (Bäumer et al 2015). The MLIC consists of 180 air-filled ionization chambers with a distance of 2 mm in beam direction, which was effectively reduced by measuring with and without an additional cover of 1.2 mm WET. In order to be able to position the phantoms and align them to the beam direction, the protons were applied from a gantry angle of 0° and the detector was set up vertically (see figure 4(a)). In addition, a solid water phantom (RW3-plates, type SP34 IBA Dosimetry, composition: 98% polystyrene + 2% TiO2) with a physical thickness of 2 mm (WET = 2.06 mm) was placed on the detector to allow stable positioning of the samples. The samples were aligned with the isocentric laser marker. The combination of thin spots with large-area stacked ionization chambers allows to study the WET of the samples within a small cross section.

Depth dose curves (DDCs) based on charge count values in the MLIC were measured downstream of the PtNP and nonPtNP samples. To be sensitive to possible pull-backs of the Bragg peak by the NPs, the thickness of the sample should be as large as possible. In order to investigate also the influence of proton energy, two samples of each type were stacked for 100, 140, 170 and 200 MeV, whereas measurements at 200 MeV were also made with four stacked samples. The single proton spots have corresponding initial spot widths $\left(\sigma \right)$ of 5.4 mm, 4.1 mm, 3.7 mm and 3.1 mm.

2.4.2. Plane parallel ionization chamber in motorized water phantom

The same experimental design with a different type of proton field and different type of detector was pursued with the PtNP and nonPtNP samples at a dedicated eye treatment beam line (IBA PT, Louvain-La-Neuve, Belgium; hereafter abbreviated as eyeline), which is similar to the one described by Slopsema et al (2013). The horizontal beam line features the single-scattering mode with residual proton ranges up to 35 mm. Consequently, only one sample with and without PtNPs was used for this setup (see figure 4(b)). Collimated 20 × 20 mm2 fields with a residual range of 35 mm and a modulation width of 35 mm (R35M35), and with a residual range of 27 mm and a modulation of 28 mm (R27M28) were used for the measurements. The kinetic energies upstream of the samples for these two field configurations vary between 56 and 64 MeV for the highest energy in the proton field based on the data base of the National Institute of Standards and Technology (NIST) (Berger et al 2005). The light field of the eyeline on the PtNP sample can be seen in figure 4(b).

The relative DDCs of the PtNP and nonPtNP samples were measured with a plane parallel ionization chamber, the PTW34045 Advanced Markus chamber (PTW, Freiburg, Germany), which was placed in the center of the quadratic field shape. An additional reference chamber (Semiflex 31 010, PTW, Freiburg, Germany) was used for dose rate normalization. A modified motorized MP3 XS water phantom (PTW, Freiburg, Germany) with an extra thin entrance window (WET of Markus chamber and phantom window = 2.22 mm) enabled step sizes of 0.1 mm in depth. The positioning of the PtNP sample in front of the thin entrance window with the help of an additional pad is shown in figure 4(b).

2.4.3. Pixelated semiconductor detector

For the third measurement setup demonstrated in figure 4(c), an innovative experimental apparatus consisting of a pixelated semiconductor counting-mode detector designed for high energy physics tracking experiments was utilized at a clinical PBS beam line, which was described in section 2.4.1. Here, the deposited energy of the protons in the detector was determined, allowing a measurement of energy loss, independent of the ionization chamber based setups mentioned above.

The chosen ATLAS IBL pixel detectors are hybrid detectors, with a 200 μm thick n-in-p silicon sensor, segmented in 80 × 336 pixels with a size of 250 × 50 μm2 (Grinstein 2013), which is bump bonded to a FE-I4B readout chip (Garcia-Sciveres et al 2011). A time over threshold signal with a 4-bit storage provides information about the number of electrons generated in the sensor, which gives the deposited energy by multiplying with the mean excitation energy for an electron-hole pair in silicon (3.6 eV (Klein 1968)). The deposited energy in the sensor yields the stopping power for the protons in 200 μm silicon. Threshold and gain of each readout channel were optimized for energy depositions between 100 keV and about 750 keV, which is close to the maximum charge the readout chip can register and fits the stopping power range of the protons entering the sensor. The hits on the sensor were spatially and temporally clustered to assign them to one initial proton. Of these, only single hit clusters were analyzed, allowing only events in which the proton has deposited its entire energy in one pixel. Subsequently, the mean value of the distribution of the deposited energy in the sensor was determined. Generally, the efficiency of the detector to register individual protons exceeds 99.9% (Weingarten 2012).

Homogeneous fields with lateral dimensions of 25 × 25 mm2 were used. PtNP and nonPtNP samples were irradiated side by side on the sensor to investigate the difference in energy deposition with and without the presence of PtNPs. The described analysis was performed in central ROIs downstream of the samples to exclude artifacts in the edge regions.

In addition, the spot sizes, defined as the sigma of the Gaussian-shaped spot profiles, were determined to investigate the effects from PtNPs on the scattering of protons. For this purpose, the time structure of the hit positions in the PBS field (step and shoot technique) was extracted. A 1D Gaussian function was fitted to each spot profile in the direction of the longer pixel edge as a summation of hits along all short pixel edges gives a higher hit statistic for each fit data point. Only spots close to the center of the respective sample were selected to exclude effects at the interface between the sample types or the detector edge. The mean spot size $\overline{{\sigma }_{\mathrm{spot}}}$ of the spots in the evaluated region downstream of each sample was calculated for every measurement.

Three samples of each type were exposed to 100 MeV protons, one sample each to 110 and 120 MeV and additionally four stacked samples each to 120 MeV. For the setups with one sample each, an additional buildup of WET = 56.2 mm consisting of one clinical range shifter (material: Polymethyl methacrylate, WET = 51 mm) and an RW3-plate of WET = 5.2 mm was placed in front of the samples to obtain the appropriate range of energy deposition in the sensor. For each setup except the one at 120 MeV and four stacked samples, the measurement with both samples was performed twice. For all measurements, the pixel detector was located in the dose gradient proximal to the peak position of the Bragg curve. Depth positions relative to R80 (the range in water at which the distal dose in the Bragg peak has reached 80%) were: 0.8 R80 for 100 MeV, 0.9 R80 for 110 MeV, 0.7 R80 for 120 MeV and one sample, and 0.8 R80 for 120 MeV and four samples.

2.5. Data interpretation

To evaluate the range measurements (setups in figures 4(a) and (b)) the DDCs were normalized and the dimensionless energy dependent quantity water equivalent ratio WER was evaluated (Zhang and Newhauser 2009). The WER is the WET normalized to the physical thickness hsample:

Equation (2)

Here the index 'sample' corresponds to 'nonPtNP' or 'PtNP', E is the initial kinetic proton energy and R80 is the range in water with or without a sample in beam path, respectively. To elaborate deviations between the depth dose curves after passing the PtNP and nonPtNP samples, WERratio(E) as the ratio between the characteristic WERsample(E) was calculated with the thickness ratio H (equation (1)) as follows:

Equation (3)

Based on this definition, an increased stopping power for protons by PtNPs would yield a WERratio less than 1.

To quantify the effect of nuclear interactions of the protons with the PtNPs, the deviation of the DDCs' charge counts for each sampling point of the DDC with and without PtNPs was determined using the measurements with the Giraffe. For this purpose, the point-wise ratio of the counts downstream of the nonPtNP sample, cntnonPtNP, to the counts downstream of the PtNP sample, cntPtNP, was calculated:

Equation (4)

Hence, positive values of DDCdev indicate a local dose decrease and negative values of DDCdev a local dose enhancement of the proton beam in the presence of PtNPs. Since deviations in the physical sample thicknesses leading to shifts in the peak region would result in large differences and misinterpretation, this analysis was performed in the entrance plateau up to the proximal R50 position (range at which the proximal dose has reached 50%). A corresponding analysis of the measurements at the eyeline was not possible, because only relative values related to the reference chamber measuring dose rate fluctuations were available.

The pixelated semiconductor sensor provides information about the deposited energy of the individual protons in the sensor. To compare the mean deposited energies downstream of the PtNP and nonPtNP samples in the sensor, $\bar{\,{E}_{\mathrm{dep},\mathrm{PtNP}}}(E)$ and $\overline{\,{E}_{\mathrm{dep},\mathrm{nonPtNP}}}(E)$, the energy dependent ratio Edep,ratio was formed:

Equation (5)

Assuming that the samples have the same physical thickness, one would expect a value of Edep,ratio less than 1 if the protons deposit more energy in the PtNP sample, since they would correspondingly deposit more energy in the downstream positioned sensor according to the Bethe Bloch formalism (Bethe 1930, Bloch 1933).

For the analysis of possible scattering effects of the protons at the PtNPs, the determined mean spot sizes, $\overline{\,{\sigma }_{\mathrm{spot},\mathrm{PtNP}}}(E)$ and $\overline{\,{\sigma }_{\mathrm{spot},\mathrm{nonPtNP}}}(E)$, downstream of the respective sample were also put into relation.

Equation (6)

With this definition, a value less than 1 would indicate an increased proton scattering in the measurements with PtNPs.

2.6. Uncertainty analysis

The uncertainties were evaluated as types A and B uncertainties based on the guide to the expression of uncertainty in measurement (Joint Committee for Guides in Metrology 2008). For assessing the uncertainties on the experimental determination of WERratio (equation (3)), the individually contributing uncertainties of H and the WET of the samples were evaluated: the ratio of sample thickness H was determined in the CT image for each sample species multiple times, resulting in the statistical type A standard uncertainty of one standard deviation σH equal to 0.021.

To determine the uncertainties on the measurements of the DDCs using known quantities, the uncertainties on the WET were analyzed for the Giraffe setup and the uncertainties on the R80 were analyzed for the water tank setup at the eyeline. Reproduction measurements with the Giraffe have yielded a type A uncertainty of 0.004 mm and measurements with respect to resolution on the WET have yielded a type B uncertainty of 0.02 mm. The total uncertainty of the WET with the Giraffe was 0.02 mm, resulting from quadratic addition, and is therefore smaller than the distance between neighboring chambers in the MLIC. Using the same setup with the water tank and the Advanced Markus chamber at the eyeline, the range was measured many times over months, allowing the uncertainty about reproducibility and thus the uncertainties of the beam and the motorized phantom to be determined as 0.11 mm. Consequently, the uncertainty on WERratio could be calculated according to Gaussian error propagation. For all measured energies with the Giraffe as well as at the eyeline, a standard uncertainty of ${\sigma }_{{{WER}}_{\mathrm{ratio}}}=0.022$ was obtained.

Experimental uncertainties on the deposited energy in the semiconductor sensor were estimated using response measurements of homogeneity and reproducibility. For this purpose, the deposited energy on the sensor downstream of a step phantom of nine different thicknesses was measured twice and another two times after the step phantom was rotated by 180°. When comparing the deposited energy of the measurement repetitions and downstream of the steps of the phantom, a type A uncertainty of 1.09% on the mean deposited energy in the semiconductor detector could be determined. The uncertainty on Edep,ratio was determined according to quadratic addition of the relative uncertainties for the mean deposited energy for the respective measurements. The maximum value for the standard uncertainty of Edep,ratio is ${\sigma }_{{E}_{\mathrm{dep},\mathrm{ratio}}}=0.016$.

Based on the knowledge that the samples' thicknesses may vary slightly, the corresponding effect on Edep,ratio is conservatively estimated in a second uncertainty analysis: assuming that one nonPtNP sample is hnonPtNP = 20 mm thick, the thickness of one PtNP sample is determined by the factor H, taking into account the uncertainty of H: ${h}_{\mathrm{PtNP}}={h}_{\mathrm{nonPtNP}}\cdot \left(H\pm {\sigma }_{H}\right)$. This assumption is based on the NIST data (Berger et al 2005) and yields a ± 1σ confidence interval for the ratio of the deposited energies in the sensor, which is [0.972; 1.036] at 100 MeV, [0.989; 1.013] at 110 MeV, [0.995; 1.007] at 120 MeV with one sample and [0.977; 1.029] at 120 MeV with four stacked samples. The corresponding deviations to the value 1 were considered as a second uncertainty.

In the spot size analysis, the experimental uncertainty downstream of the PtNP and nonPtNP sample was given by the standard uncertainty of the spot sizes of different positions for the respective measurement. For the ratio, the total uncertainty was calculated using Gaussian error propagation, with the largest value being ${\sigma }_{{\sigma }_{\mathrm{spot},\mathrm{ratio}}}=0.014.$

3. Results

3.1. Impact on treatment planning

A transversal CT slice to verify the sample properties is shown in figure 5. Based on the contracted ROIs highlighted in green in figure 5, a contrast ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ of about 6 HU was found, so $\overline{{{CT}}_{\mathrm{num}}}$ of the PtNP samples is larger than that of the nonPtNP samples (see section 2.3). Therefore, an offset of 3 HU was used for contouring the 50% sample level outline when determining the physical sample thickness. The analysis revealed the ratio H = 0.997(21). Since the outer contours presented in figure 5 are gray level based with largely straight parallel lines, almost homogeneous sample thicknesses were assumed.

Figure 5.

Figure 5. Transversal computed tomography (CT) slice of the samples: samples with platinum nanoparticles (PtNP samples) are shown in (a) and samples without platinum nanoparticles (nonPtNP samples) in (b). Additionally, the mean CT contrast ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ and the standard deviation of the mean in concise notation is specified. The blue regions show the gray level based contoured outer contours and the green regions are the contours contracted by 5 mm used for the sample's $\overline{{{CT}}_{\mathrm{num}}}$ determination.

Standard image High-resolution image

This CT contrast ${\rm{\Delta }}\overline{{{CT}}_{\mathrm{num}}}$ from the PtNPs applied to voxels of the target volume in three clinical pediatric brain tumor plans, would result in a mean density increase of 0.005 g cm−3 in the PTV. The values of the difference in dose coverage ΔD98% of the PTV due to the density change resulted in 0.04%, 0.16% and −0.13% for the tested patients.

3.2.  WER comparison from depth dose measurements

The results of the depth dose distributions with varying proton energies and field configurations with and without PtNPs are shown in figure 6. Since it is known from the CT analysis that the PtNP and nonPtNP samples are potentially not equally thick (see section 3.1), the measured values were in first order corrected with the known ratio of H. With this, the DDCs of the nonPtNP and the PtNP samples for the mono-energetic fields in figure 6(a) as well as the energy modulated fields in figure 6(b) are consistent. The experiment with the highest energy of 200 MeV and four stacked samples of each type is an exception: the dose distribution of the PtNP sample is shifted proximally by about 0.9 mm in comparison to the depth dose with the nonPtNP sample in the beam path (see magnification in figure 6(a)).

Figure 6.

Figure 6. Measured depth dose curves (DDCs) in water of proton fields with different initial energy after traversing samples without platinum nanoparticles (nonPtNP, light blue line) and with platinum nanoparticles (PtNP, dashed red line) in comparison. (a) Presents the measurements with the Giraffe detector for mono-energetic fields. Except for the graphs marked with the grayed 200 MeV, two samples were used. The grayed 200 MeV insert indicates that four samples were used for these measurements. The magnification indicates a small shift of 0.9 mm (dark green double arrow) of the DDCs downstream of the PtNP and nonPtNP samples. The lower plot indicates the deviation of the detector counts DDCdev for each sampling point (see equation (4)). The measurements at the eyeline in the water phantom with the Advanced Markus chamber and energy modulated fields are shown in (b).

Standard image High-resolution image

The deviations of the DDCs' count values DDCdev (see equation (4)) indicate positive values, for all except the measurement at 200 MeV with four stacked samples. But the deviations for each sampling point are smaller than 2% for depths less than the proximal 50% of the Bragg peak.

Table 1 presents the calculated WERratio values of the nonPtNP and PtNP samples based on equation (3) for the various field configurations and experimental setups of the depth dose measurements. The number of samples refers to the number per sample type, i.e. for PtNP and nonPtNP, respectively. The values of WERratio are consistent to 1 for all measurements, independent from the energy or the number of samples, including the one with four samples each at 200 MeV.

Table 1. Values of the dimensionless quantity WERratio (see equation (3)) with its standard uncertainty ${\sigma }_{{{WER}}_{\mathrm{ratio}}}$ in concise notation.

 Mono-energeticEnergy modulated
Field configuration100 MeV140 MeV170 MeV200 MeVR27M28R35M35
Number of samples2222411
WERratio 1.008(22)1.008(22)1.008(22)1.008(22)0.986(22)0.999(22)0.998(22)

3.3. Energy deposition and spot sizes

Figure 7 illustrates the distribution of the deposited energy in the sensor of a representative measurement with the pixel detector. These deposited energies of the initial protons in the sensor, Edep,PtNP and Edep,nonPtNP, are given as histograms, where the bin size is optimized for the range of measured deposited energy in the sensor. The mean deposited energy in 200 μm silicon downstream of the PtNP sample is $\overline{){E}_{\mathrm{dep},\mathrm{PtNP}}}$ = 375(4) keV and downstream of the nonPtNP sample $\overline{){E}_{\mathrm{dep},\mathrm{nonPtNP}}}$ = 368(4) keV. These values are indicated by the dashed red line. Considering the experimental uncertainties of 1.09%, the values of the mean deposited energy downstream of the PtNP sample and the nonPtNP sample are comparable.

Figure 7.

Figure 7. Distribution of the deposited energy in the semiconductor pixel detector of proton fields with 120 MeV initial energy after traversing a buildup of 56.2 mm water equivalent and one sample of each type. (a) shows the energy distribution deposited in the sensor downstream of the sample with platinum nanoparticles (PtNP) and (b) of the sample without platinum nanoparticles (nonPtNP). The dashed red line indicates the mean value, $\overline{){E}_{\mathrm{dep},\mathrm{PtNP}}}$ and $\overline{){E}_{\mathrm{dep},\mathrm{nonPtNP}}}$, of the deposited energy.

Standard image High-resolution image

Table 2 summarizes the results of the ratio of the mean energy deposition Edep,ratio(E) in the pixel detector for each setup and initial proton energy (equation (5)). The number of samples refers to each sample type and the absorber in the setup indicates the additional buildup of WET = 56.2 mm. The standard uncertainty of Edep,ratio is written in concise notation and the second uncertainty analysis considering the different sample thicknesses is given as the upper and lower limit of the ± 1σ confidence interval. The values for the ratio of the mean deposited energy Edep,ratio downstream of the samples are approximately 1 for 100 and 110 MeV, whereas the values for Edep,ratio at 120 MeV are below 1 considering the experimental uncertainties. With additional consideration of the second uncertainty analysis for thickness variation, only the value of ${E}_{\mathrm{dep},\mathrm{ratio}}=0.973{\left(15\right)}_{-0.005}^{+0.007}$ is not consistent to 1 within the whole uncertainty budget.

Table 2. Values of the ratio of the mean energy depositions Edep,ratio as well as the ratio of the spot sizes σspot,ratio in the pixel detector.

Energy (MeV)Setup $\overline{){E}_{\mathrm{dep},\mathrm{sample}}}$ (keV) Edep,ratio σspot,ratio
  PtNPnonPtNP  
1003 samples stacked510(6)521(6) $1.022{\left(16\right)}_{-0.028}^{+0.036}$ 1.14(14)
  508(6)520(6) $1.024{\left(16\right)}_{-0.028}^{+0.036}$ 1.02(10)
1101 sample, absorber556(6)552(6) $0.993{\left(16\right)}_{-0.011}^{+0.013}$ 0.95(11)
  558(6)555(6) $0.995{\left(16\right)}_{-0.011}^{+0.013}$ 1.13(11)
1201 sample, absorber377(5)367(4) $0.973{\left(15\right)}_{-0.005}^{+0.007}$ 1.03(8)
  375(4)368(4) $0.981{\left(16\right)}_{-0.005}^{+0.007}$ 0.96(5)
 4 samples stacked382(5)392(5) $1.026{\left(16\right)}_{-0.023}^{+0.029}$ 1.00(8)

While Edep,ratio is a measure of the mean values of the deposited energy, the statistical contribution of the shape of the energy distribution was tested under the assumption of equal mean values using the Mann-Whitney U test. This assumption was made because of the known differences in sample thicknesses. The test showed for all distributions of deposited energy downstream of the PtNP and nonPtNP samples of the respective measurement that they are not significantly different at α = 5% significance level.

The determined values for the spot size ratio σspot,ratio downstream of the PtNP and nonPtNP samples are also listed in table 2. The results show that the spot sizes agree within their experimental uncertainties except for the second measurement at 110 MeV. For the latter, the spots downstream of the nonPtNP sample are larger than the spots downstream of the PtNP sample, based on the definition in equation (6).

4. Discussion

This study establishes aspects in the energy domain for the underlying mechanisms behind the radiosensitizing effect of PtNPs in proton therapy. For this purpose, the ability of ROS generation of surfactant-free colloidal PtNPs of different concentrations was verified previously, indicating the potential of an enhanced therapeutic effect of radiotherapy by these PtNPs (figure 2). The fact that a higher concentration of PtNPs increases 2-OH-TA production can be attributed to the larger available surface area (Zwiehoff et al 2021). Manufactured gelatin samples without and with the same PtNPs of the highest demonstrated concentration were irradiated with protons and the downstream energy deposition was analyzed.

Based on the quantity WERratio and considering their uncertainties, no difference in the WER of samples with and without PtNPs in the beam path could be verified from the depth dose distributions (figure 6 and table 1). Since the WER is a measure of the stopping power for protons, the latter is not increased under the involvement of the platinum NPs used. Furthermore, the ratio of the mean deposited energies Edep,ratio(E) downstream of the PtNP and nonPtNP samples is approximately 1 for nearly all measurements with the pixel detector as presented in figure 7 and table 2. Thus, the stopping power for the protons in the silicon downstream of the PtNP and nonPtNP samples is also similar. According to the unchanged stopping power in the depth dose measurements and the measurements of the deposited energy in the pixel detector, the protons did not deposit more energy, and thus physical dose, in the presence of the PtNPs at the macroscopic scale.

The small difference in the DDCs downstream of the four stacked PtNP and nonPtNP samples and initial energy of 200 MeV in figure 6 might initially indicate an increased energy deposition due to the PtNPs. However, looking at WERratio, this difference is within the uncertainty, which is mainly dominated by the thickness determination of the samples (see table 1).

The additional analysis of the absolute DDCs (see lower part in figure 6) shows that there is a small deviation of less than 2% in the detector counts downstream of PtNP samples and nonPtNP samples up to a depth of the proximal 50% of the Bragg peak. An analysis in the peak region would lead to large deviations in the gradient due to small range mismatches. Normalization to R80 to compensate for these mismatches was not performed given the approaches of this study. According to the results, the total deposited energy of the protons after penetrating the PtNP and nonPtNP samples is comparable on a macroscopic scale. This indicates that the effect of nuclear interactions of protons and PtNPs is small, which otherwise could have been a further explanation for the radiosensitizing effect of PtNPs.

For a more detailed discussion of the results of Edep,ratio measured with the pixel detector, it is essential to consider the second uncertainty analysis, since Edep,ratio does not include the uncertainty on the sample thickness (see table 2). From the CT analysis (subsection 3.1) it is known that the samples may not be of equal thickness. Taking this into account, one value of Edep,ratio is outside the ±1σ confidence interval, but nevertheless in the uncertainty of 2σ. Considering all measurements in this study, there is one result out of 14 measurements, that deviates more than the 1σ uncertainty, which is assumed to be statistically expected.

In order to compare the overall distribution of deposited energy in addition to the mean deposited energies, a Mann-Whitney U test was performed, which showed that the distributions are not significantly different (α = 5%), assuming the same mean value. The evaluation of the energy depositions indicates that the particles, which leave the different kind of samples, belong to the same population with a high level of confidence.

Due to the fact that for the measurements at 110 and 120 MeV the same buildup absorber was used, which results in different relative pixel detector depth positions in the Bragg curves, a possible position dependence of the detector in the depth domain may affect the sensitivity of the results. However, when comparing the measurements at 120 MeV with two different setups and detector depth positions, this effect seems unlikely. This is because the measurement with four samples, for which the detector position is at a larger depth, shows a value of Edep,ratio larger than 1 and thus does not indicate an increased proton energy deposition in the presence of PtNPs.

The spot sizes downstream of the PtNP and nonPtNP samples agree within their standard uncertainties for most measurements with the pixel detector, indicating that the presence of PtNPs does not affect the multiple Coulomb scattering of protons. The measurement at 110 MeV, where the spot sizes downstream of the various samples differ, also shows no increased scattering of protons by the PtNPs, since the spot size downstream of the nonPtNP sample is larger than that downstream of the PtNP sample. Thus, one of the measurements is not within the ±1σ interval, which is statistically expected.

The presented macroscopic effects in the Bragg peak shape in Ahmad et al (2016), where gold nano-films with higher concentrations such as 5.5 mg ml−1 were used, could not be confirmed in this study (figure 6), which may suggest that nano-films are not comparable to NPs.

The dose increase from the radiosensitizing effect of metal NPs expected in other works is not evident in this study because it is assumed to be very localized around the NPs (Sicard-Roselli et al 2014, Wälzlein et al 2014, Cho et al 2016). The deposited energy in the experiments presented here is measured macroscopically downstream of the samples and not microscopically in the immediate vicinity.

During the measurements with the Giraffe and the pixel detector, the samples were located in the entrance region, i.e. the clinically less relevant part, of the Bragg curve. However, the measurements at the eyeline with the modulated proton beam, where the samples were in the spread-out Bragg peak, led to the same results. Thus, the findings are generalizable on a macroscopic scale, regardless of the Bragg curve region in which the PtNPs are located. Further experiments should investigate whether there are influences at the microscopic scale, for example, due to the different proton LET, as described in Li et al (2016) for AuNPs.

The analysis of the sample parameters in a CT was performed on randomly selected samples. Two samples of each type were scanned. The calculated thickness ratio was assumed to apply for all PtNP and nonPtNP samples on average, respectively. Accordingly, deviations in the WER of the samples or the mean deposited energy downstream of them due to improperly corrected sample thickness may be explained if more than two samples were used for the measurement.

In addition, the CT scan has shown a higher contrast of the PtNP samples compared to the nonPtNP samples. Hence, the therapeutic use of metal NPs may affect clinical imaging like CT due to the high x-ray absorption coefficient of gold and platinum. Previous studies with AuNPs and higher concentrations than the one used in this study have already presented the possible use of NPs as nontoxic contrast agents in CT (Hainfeld et al 2013, Silvestri et al 2016, Han et al 2019). Furthermore, comparable CT contrast as an attenuation of about 8 HU was found with gadolinium at the same concentration (Kim et al 2018).

Based on investigations of the proton range, energy deposition and lateral scattering at various initial energies, this study indicates that the dose computed in the treatment planning of proton therapy is unaffected by PtNPs, although the planning CT would indicate an increased HU number. For a more detailed statement, three exemplary clinical treatment plans for brain tumors where used, to recalculate the original highly conformal dose distribution in the planning target volume assuming that the target volume would have the CT contrast of 6 HU more. However, the associated increase in mean density of 0.005 g cm−3 and stopping power based on the increased CT numbers compromises the dose coverage D98% of the planning target volume below 0.2%. Moreover, contrary to expectations, the negative value for ΔD98% may be due to variations introduced by the voxel grid.

This study only involves physical experiments in which biological factors like cellular uptake or toxicity were not considered. In order to place large amounts of high-Z material in the beam path, a mass concentration of 300 μg ml−1 of colloidal NPs (0.03 wt% PtNPs in gelatin) with a mean diameter of (40 ± 10) nm was used. These PtNPs with relatively high concentrations and a large diameter compared to similar studies (Zwiehoff et al 2021) were shown to lead to an increased concentration of damaging radicals in the form of 2-OH-TA by a factor of about 2 under proton irradiation compared to samples without PtNPs (figure 2). Thus, in this study, the focus was not on a clinically applicable concentration, but on a potentially high enhancement effect of proton therapy.

Based on these experiments, the radiosensitizing effect of PtNPs in proton therapy is not due to an increased proton energy deposition at the macroscopic scale. This confirms Dollinger's (Dollinger 2011) considerations that only a tiny fraction of the proton energy is transferred to the PtNPs themselves. Although the elementary mechanism behind the radiosensitizing effect of PtNPs in proton therapy remains an open question, these measurements finally provide further evidence for the catalytic effect of PtNPs in addition to previous ROS measurements (Zwiehoff et al 2021). For this reason, further chemical investigations could elucidate the underlying mechanisms of the radiosensitizing effect of NPs.

5. Conclusions

In this study, experimental evidence was provided that clinical proton fields do not deposit an increased amount of energy in the presence of ROS-producing PtNPs at the macroscopic scale. For this purpose, various measurements of proton stopping power downstream of (40 ± 10) nm sized colloidal PtNPs at a concentration of 300 μg ml−1 were performed in comparison to samples without PtNPs. It was shown that there is macroscopically no enhanced effect in the water equivalent ratio as well as in the mean deposited energy downstream of the samples in the presence of PtNPs under these conditions. Moreover, the spot sizes were not affected by the protons' scattering at NPs. In clinical application, this corroborates uncomplicated treatment planning, since the dose in the target volume with NPs does not have to be additionally corrected.

As a result, this study could experimentally confirm mechanisms and theories already suspected in the literature regarding the radiosensitizing effect of noble metal NPs and serve as further evidence for the catalytic effect of NPs. Nevertheless, the employed types of experiment were not designed to explain the microscopic mechanism and cannot clarify the background of the radiosensitizing effect, but merely provide further insight into this highly interesting but not yet fully explored field of radiobiology.

Acknowledgments

The presented study was supported by the MERCUR-Stiftung graduate school "Präzisionsprotonentherapie—Praxisbezogene Physik und Chemie an der Schnittstelle zur Medizin" (grant number St-2019-0007) and the project "Synergistische Effekte von Gold-Nanopartikeln und Protonenbestrahlung bei der Behandlung von Hirntumoren im Kindesalter" (SYNGOPRO, grant number EFRE-0801289), which is funded by the European fund for regional development (EFRE). The authors would like to thank Horst Fischer and Michael Weber from Department of Dental Materials and Biomaterials Research RWTH Aachen University Hospital for gelation of the samples. In addition, the authors are grateful to the IBA PT and the WPE physics team for their experimental support. Special thanks to Benjamin Koska, for the commissioning data of the eyeline. Furthermore, Valerie Hohm (TU Dortmund) is acknowledged for her support with the silicon detector measurements.

Conflicts of interest

The authors declare no conflict of interest.

Please wait… references are loading.
10.1088/1361-6560/ac80e6